Table 2

Clinical characteristics of patients with proven and probable monogenic NDM and probable T1D

Proven monogenic NDM <6 months, n = 194Probable monogenic NDM <6 months (T1D-GRS ≤50th T1D centile), n = 27Probable T1D <6 months (T1D-GRS >50th T1D centile), n = 21P value (proven monogenic vs. probable monogenic)P value (proven monogenic vs. probable T1D)
T1D-GRS, median (IQR)0.231 (0.206–0.251)0.237 (0.210–0.250)0.299 (0.295–0.313)0.86<0.001
Age at diagnosis in weeks, median (IQR)5 (1–12)1 (0.6–6)12 (3–20)0.130.04
Male, n (%)111 (57)17 (63)15 (71)0.680.25
Presence of other autoimmune disorders, n (%)1 (1)1 (4)3 (14)0.230.003
Syndromic presentation, n (%)77 (40)9 (33)2 (10)0.670.007
Consanguineous parents, n (%)3 (2)001.001.00
  • NDMX patients were categorized into probable T1D and probable monogenic NDM by T1D-GRS equivalent to 50th centile of T1D cohort. Fisher exact test was used to compare proportions, and Mann-Whitney U test was used to compare continuous variables. IQR, interquartile range.